Changes in the outpatient prescription market as Korean largest selling products advance
RosuzetㆍGliataminㆍK-CAB rank at Top 5… half of Top 10ㆍTop 20 are Korean drugs The ranking of the outpatient prescription market is rapidly changing.
While foreign affiliates’ bestselling drugs struggled in the aftermath of COVID-19, Korean largest selling products are raising their rankings with dramatic growth.
In 1Q, Lipitor (Pfizer) took the lead in the outpatient prescription market, followed by Rosuzet (Hanmi Pharmaceutical), Gliatamin (Daewoong Bio), and K-CAB (HK inno.N).
Gliatamin reached third place in 1Q of last year, but Rosuzet and K-CAB have grown significantly, entering the top five.
K-CAB’s quarterly prescriptions surged more than 10 billion won YoY, and it rose from 27th to 4th.
Accordingly, half of the Korean drugs were filled in the Top 5, unlike last year, when Gliatamin was the only Korean product.
With the addition of Rosuzet and K-CAB, Tagrisso (AstraZeneca) and Plavix (Sanofi) were pushed out of the top five.
Twynsta (Boehringer Ingelheim) also fell from fourth to fifth but remained in the top 5.
Among the 6th and 10th places, Zemimet (LG Chem) and Chongkundang Gliatirin (Chong Kun Dang Pharmaceutical) were newly added, accounting for half of the top 10 drugs as Korean products.
In 1Q of last year, only three of the top 10 products were South Korean, including Gliatamin, Rosuzet, and Amosartan (Hanmi Pharmaceutical), but with the addition of K-CAB, Zemimet, and Gliatirin and withdrawal of Amosartan, the number increased to five.
Even outside of the top 10, Korean companies performed well. Amosartan fell below the top 10, but Korean companies accounted for half of the top 11-20 as Eutropin (LG Chem) and Godex (Celltrion) were newly joined, with Aricept (HANDOK) and Livaro (JW Pharmaceutical), which were previously placed between 11th and 20th.
Compared to last year, the number of Korean drugs rose from three to five in the top 10 list and seven to ten in the top 20.
The proportion of Korean products’ prescription was only 27.1% between the first and 10th places last year, but this year it surged to 47.3%, and from 33.2% to 48.5% for the first to 20th.